Topic

Articles

Diurnal Group has been granted a patent for its hydrocortisone granules in capsules for opening, Alkindi, from the European Patent Office.

Diurnal Receives Patent Grant from European Patent Office

Kevin E. Noonan, PhD, noonan@mbhb.com, is partner at McDonnell Boehnen Hulbert & Berghoff LLP and chair of the firm’s Biotechnology & Pharmaceuticals Practice Group.

Opposition to IP protection for COVID-19 vaccines, therapies, tests and other technologies may only prevent eradication and treatment of the disease.

Protecting Intellectual Property for COVID-19 Innovations

The register supports cross-functional teams of chemists and biologists in developing non-natural, chemically-modified therapeutics for drug discovery.

Dotmatics Launches Bioregister 2020.1

In the study, GigaGen presents a novel technology for producing a new class of drug, recombinant hyperimmunes, that may potentially generate new COVID-19 therapies.

GigaGen Highlights Research Describing New Class of Drugs for Potential COVID-19 Therapy

Jane E. Remillard is the leader of the Life Sciences Intellectual Property Team at Nelson Mullins, jane.remillard@nelsonmullins.com

Jill Gorny Sloper is a partner at Nelson Mullins with a focus on patent law in the biotechnology, pharmaceutical, and life science fields, jill.sloper@nelsonmullins.com

Stringent patentability requirements present a challenge to obtaining broad-based antibody claims, so companies should develop a strategy based on multiple reinforcing layers of protection. 

Patentability Considerations for Antibody-Related Inventions

FDA’s EUA provides the first new treatment for COVID-19 patients with severe symptoms.

Remdesivir Approved for Emergency Use

Eurofins DiscoverX partners with VelaLabs to enable VelaLabs to perform highly reproducible potency lot release assays under GLP/GMP conditions.

Eurofins DiscoverX Grants Bioassay Certification to VelaLabs

Under the agreement, ERS Genomics will license its gene-editing technology to Aelian Biotechnoloy to support its commercial functional genomic screening platform.

ERS Genomics, Aelian Biotechnology in CRISPR/Cas9 License Agreement

ERS Genomics revealed that the European Patent Office (EPO) has rejected arguments filed in opposition to patent EP2800811, which is directed to the single-guide CRISPR/Cas9 gene editing system and covers uses in cellular and non-cellular settings.


EPO Confirms Novelty of CRISPR/Cas9 Gene Editing System Patent

Inflazome, a biotech company based in Dublin, Ireland, has announced that the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) will grant its patent applications in January 2020.


Intellectual Property & Patents